GSK plc (GSK.L)
| Previous Close | 1,673.00 |
| Open | 1,685.50 |
| Bid | 1,713.00 x 0 |
| Ask | 1,713.50 x 0 |
| Day's Range | 1,673.00 - 1,714.50 |
| 52 Week Range | 1,302.60 - 1,725.81 |
| Volume | |
| Avg. Volume | 8,394,194 |
| Market Cap | 70.004B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 14.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.64 (3.83%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
- CNW Group
University of Toronto scientists appointed as GSK chairs will advance drug delivery research and vaccine education tools for healthcare professionals
The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs. These appointments represent the collaborative efforts between the two organizations to advance the field of pharmacy and drive positive change in patient care.
- CNW Group
GSK Canada expands charitable partnerships to include support of environmental sustainability and STEM
GSK is proud to announce new charitable partnerships in STEM (science, technology, engineering and math) education for underrepresented communities and environmental sustainability. The company's newest philanthropic collaborations are an exciting opportunity to support our commitment to the health of our planet and the next generation of scientists in an equal and inclusive manner.
- Business Wire
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
